Preliminary results from a phase I study of nivolumab Y90 TARE in patients with advanced HCC found a DCR of 82% (n = 9 with stable disease), and 46% (n = 6) experienced a decrease in AFP [279]. Here, AFP is linked to hepatocellular carcinoma.